EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation

Esa Jantunen, Antti Turunen, Ville Varmavuo, Anu Partanen iD

Transfusion · 2024

DOI: 10.1111/trf.17755 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transfusion, 2024. Verfasst von Esa Jantunen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Heterocyclic Compounds, Hematopoietic Stem Cell Transplantation, Multiple Myeloma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plerixafor (PLER), a reversible antagonist of the CXC chemokine receptor type 4, has been in clinical use for mobilization of blood grafts for autologous hematopoietic cell transplantation (AHCT) for about 15 years. Initially PLER was investigated in placebo‐controlled trials with the granulocyte colony‐stimulating factor (G‐CSF) filgrastim. It has also been used in combination with chemotherapy plus G‐CSF in patients who had failed a previous mobilization attempt or appeared to mobilize poorly with current mobilization (preemptive use). This review summarizes what is known regarding addition of PLER to standard mobilization regimens. PLER increases mobilization of CD34 + cells, decreases the number of apheresis sessions needed to achieve collection targets and increases the proportion of patients who can proceed to AHCT. It appears also to increase the amount of various lymphocyte subsets in the grafts collected. In general, hematologic recovery after AHCT has been comparable to patients mobilized without PLER, although slower platelet recovery has been observed in some studies of patients who mobilize poorly. In phase III studies, long‐term outcome has been comparable to patients mobilized without PLER. This also appears to be the case in patients receiving plerixafor for poor or suboptimal mobilization of CD34 + cells. In practice, PLER is safe and has not been shown to increase tumor cell mobilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic CompoundsHematopoietic Stem Cell TransplantationMultiple MyelomaHumansHematopoietic Stem Cell MobilizationGranulocyte Colony-Stimulating FactorTransplantation, AutologousAntigens, CD34

Stichwörter der Autor:innen

CD34+ cell mobilizationautologous hematopoietic cell transplantationgraft cellular compositionlymphomamyelomaoutcomeplerixafor

Substanzen

Heterocyclic CompoundsGranulocyte Colony-Stimulating FactorAntigens, CD34

Autor:innen und Institutionen

  • Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Department of Medicine, Kymenlaakso Central Hospital, Kotka, Finland.

ORCID-Profile: Anu Partanen

Zitieren

APA

Jantunen, E., Turunen, A., Varmavuo, V., & Partanen, A. (2024). Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation. Transfusion. https://doi.org/10.1111/trf.17755

Vancouver

Jantunen E, Turunen A, Varmavuo V, Partanen A. Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation. Transfusion. 2024. doi:10.1111/trf.17755

BibTeX
@article{Jantunen2024,
  author = {Jantunen, Esa and Turunen, Antti and Varmavuo, Ville and Partanen, Anu},
  title = {Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.17755}
}
Kostenlos starten →